Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-26 (chosun.com)
Biogen returns North American rights for Samsung Bioepis eye treatments -
Biogen returns North American rights for Samsung Bioepis eye treatments Biogen hands back rights to eye disease treatments from Samsung Bioepis in Nor
Read more
2024-09-27 (investing.com)
Sage regains rights to SAGE-324 as Biogen withdraws from partnership By Investing.com
Sage regains rights to SAGE-324 as Biogen withdraws from partnership
Read more
2024-01-11 (fiercepharma.com)
Biogen returns ex-U.S. rights of MS drug Fampyra to Acorda
With sales declining for aging multiple sclerosis (MS) drug Fampyra, Biogen has exercised an option to
Read more
2023-02-22 (informa.com)
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
Read more
2023-02-22 (informa.com)
Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation
Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.
Read more
2023-02-15 (fool.com)
Biogen (BIIB) Q4 2022 Earnings Call Transcript
BIIB earnings call for the period ending December 31, 2022.
Read more
2022-10-01 (biocentury.com)
Life Sciences Cares: mobilizing biotechs to local community action and immediate impact
With growing footprints in four biopharma hubs and a fifth on the way, Life Sciences Cares is organizing companies to alleviate poverty and inequality in t...
Read more
2014-03-21 (genengnews.com)
Biogen Idec Gives Worldwide AV-203 Rights Back to Aveo
Aveo Oncology has regained worldwide rights to its clinical-stage ErbB3 inhibitory antibody candidate AV-203 from Biogen Idec.
Read more